Ipsen : Feedback 2020 CMD - Target: broadening of the portfolio – target price: € 89
>Increase in R&D and M&A - The aim of the Capital Market Day was for the new CEO to present his strategic initiatives and the elements of the group's trajectory by 2024.Ipsen's management wants to enrich the pipeline by increasing its R&D investments (probably around 20%+ in the long term vs 15.5% in 2019), and by making asset acquisitions (products and technologies, licences, etc.), with an estimated budget of € 3bn over the duration of the plan. The group is ta...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.